ValiRx today confirmed preliminary information from phase I/II trials of VAL201, its lead compound, will be available in the first quarter of this year.
ValiRx COO Morris highlights ‘very important year’ for company
Quick facts: ValiRx PLC
Price: 0.1314 GBX
Market Cap: £1.35 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of ValiRx PLC named herein, including the promotion by the Company of ValiRx PLC in any Content on the Site, the Company receives from said issuer...FOR OUR FULL DISCLAIMER CLICK HERE